Prevalence percentages and odds ratios for primary outcome (death or loss-to-follow-up) from the logistic regression analysis.

<p>OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; SD: Standard deviation; PI: Protease inhibitor; Anaemia: Haemoglobin concentration <12 g/dL in women and <13 g/dL in men.</p><p>Prevalence percentages and odds ratios for primary outcome (death or loss-to-follow-up) from the logistic regression analysis.</p

Clinical baseline characteristics of study population.

<p>IQR: Interquartile range.</p><p>WHO definition of Anaemia: Haemoglobin concentration <12 g/dL in women and <13 g/dL in men.</p><p>Clinical baseline characteristics of study population.</p

CONSORT diagram for analysis, with a total number of enrolled patients, number of patients for survival analysis and number of patients to estimate risk factors for attrition.

<p>CONSORT diagram for analysis, with a total number of enrolled patients, number of patients for survival analysis and number of patients to estimate risk factors for attrition.</p

Attrition Rate at 36-month follow up of the cohort in the public sector comparing with MSF (H) cohort.

<p>N: Number; LTF: Loss to follow up; MSF (H): Médecins Sans Frontières (Holland); DOH: Department of Health.</p><p>Attrition Rate at 36-month follow up of the cohort in the public sector comparing with MSF (H) cohort.</p

Unadjusted Kaplan-Meier curves, by first-line ART regimen.

<p>Unadjusted Kaplan-Meier curves, by first-line ART regimen.</p

Flexible parametric survival model of potential determinants for attrition among study population (N = 5,718).

<p>CI: Confidence interval; BMI: Body mass index; PI: Protease inhibitor; WHO definition of Anaemia: Haemoglobin concentration <12 g/dL in women and <13 g/dL in men.</p><p>#- not significant in univariate models.</p><p>Note: Early enrolment (1 Sep 2005 to 31 Dec 2009), and Late enrolment (1 Jan 2010 to 20 Oct 2011).</p><p>Flexible parametric survival model of potential determinants for attrition among study population (N = 5,718).</p

Unadjusted Kaplan-Meier survival curves of non-prior ART group and prior ART group, full cohort (N = 10,223).

<p>Log-rank test for equality of survival χ2 (1 df) = 122.10; p<0.001.</p

Clinical baseline characteristics of study population, continued.

<p>BMI: Body mass index; SD: Standard deviation; NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor.</p><p>Clinical baseline characteristics of study population, continued.</p